Innova Captab Limited Share Price & Analysis
₹1049.70−1.21%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹1049.70−1.21%Open
₹1062.60High
₹1066.90Low
₹1044.00Close
₹1049.7052W High
₹1354.0052W Low
₹608.00Volume
18KLot Size
1Sector
HealthcareMarket Cap
₹6K CrFace Value
₹10Mid Cap
Price Chart
Candle
Range
Fundamentals
P/E
36.70Sector P/E
50.20P/B
—EPS
₹26.91ROE
13.70%ROCE
15.00%D/E Ratio
0.32Div Yield
0.20%Book Value
₹191.00Strengths
- Efficient capital deployment (ROCE 15%)
- Attractively valued vs sector (P/E 36.7x vs industry 50.2x)
- Low debt relative to equity (D/E 0.3x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
INNOVACAP · as of Mar 2026
Promoters50.90%
FII0.35%0.39pp
DII19.77%0.19pp
Public29.00%0.59pp
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% |
| FII | 3.57% | 1.94% | 1.19% | 1.01% | 0.74% | 0.35% |
| DII | 10.31% | 20.78% | 21.24% | 20.61% | 19.96% | 19.77% |
| Public | 35.22% | 26.39% | 26.67% | 27.48% | 28.41% | 29.00% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and other business matters
Results6 May 2026
Interim Dividend - Rs 2 Per Share
Dividend29 Jan 2026
Latest News
All newsInnova Captab announces board meeting outcomes
*Innova Captab announces board meeting outcomes.* The company disclosed outcomes from its recent board meeting held on September 03, 2026. Specific resolutions included **approval of financial updates** and **proposal for a private placement**. Further details will be disclosed in upcoming filings. 📊 *STOCKS:* $INNOVACAP | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Corporate
NSE Filing3 Sept
Innova Captab's 22nd AGM postponed to later date
*Innova Captab's 22nd AGM postponed to later date* as per a regulatory filing. The new date for the Annual General Meeting has not been disclosed yet. The postponement is in compliance with SEBI LODR regulations. Earlier intimation was issued on **04th June 2026**. 📊 *STOCKS:* INNOVACAP | 🏢 *SECTOR:* Corporate | #LOWIMPACT #AGM
NSE Filing24 Jun
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹450 Cr 18.4% | ₹380 Cr 8.0% | ₹352 Cr 11.7% | ₹315 Cr 0.3% | ₹316 Cr 0.6% | ₹318 Cr 8.2% | ₹294 Cr 11.8% | ₹263 Cr |
| Op. Profit | ₹69 Cr 32.7% | ₹52 Cr 0.0% | ₹52 Cr 8.3% | ₹48 Cr 2.1% | ₹47 Cr 6.0% | ₹50 Cr 19.0% | ₹42 Cr 10.5% | ₹38 Cr |
| OPM | 15.0% 7.1% | 14.0% 6.7% | 15.0% 0.0% | 15.0% 0.0% | 15.0% 6.3% | 16.0% 14.3% | 14.0% 0.0% | 14.0% |
| Net Profit | ₹42 Cr 40.0% | ₹30 Cr 3.2% | ₹31 Cr 3.3% | ₹30 Cr 11.8% | ₹34 Cr 2.9% | ₹35 Cr 20.7% | ₹29 Cr 0.0% | ₹29 Cr |
| EPS (₹) | 7.37 42.3% | 5.18 4.4% | 5.42 4.8% | 5.17 13.5% | 5.98 2.3% | 6.12 18.8% | 5.15 2.6% | 5.02 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.6K Cr 31.0% | ₹1.2K Cr 15.1% | ₹1.1K Cr 16.7% | ₹926 Cr 15.6% | ₹801 Cr 94.9% | ₹411 Cr 10.2% | ₹373 Cr 4.8% | ₹356 Cr |
| Expenses | ₹1.4K Cr 31.2% | ₹1.1K Cr 14.0% | ₹927 Cr 14.0% | ₹813 Cr 15.5% | ₹704 Cr 97.8% | ₹356 Cr 10.6% | ₹322 Cr 2.2% | ₹315 Cr |
| Op. Profit | ₹243 Cr 30.6% | ₹186 Cr 20.8% | ₹154 Cr 35.1% | ₹114 Cr 18.8% | ₹96 Cr 77.8% | ₹54 Cr 5.9% | ₹51 Cr 24.4% | ₹41 Cr |
| OPM | 15.0% 0.0% | 15.0% 7.1% | 14.0% 16.7% | 12.0% 0.0% | 12.0% 7.7% | 13.0% 7.1% | 14.0% 27.3% | 11.0% |
| Other Income | ₹7 Cr 41.7% | ₹12 Cr 0.0% | ₹12 Cr 33.3% | ₹9 Cr 200.0% | ₹3 Cr 200.0% | ₹1 Cr 0.0% | ₹1 Cr | ₹0 Cr |
| Interest | ₹17 Cr 750.0% | ₹2 Cr 90.5% | ₹21 Cr 5.0% | ₹20 Cr 233.3% | ₹6 Cr 50.0% | ₹4 Cr 20.0% | ₹5 Cr 16.7% | ₹6 Cr |
| Depreciation | ₹45 Cr 80.0% | ₹25 Cr 56.3% | ₹16 Cr 45.5% | ₹11 Cr 37.5% | ₹8 Cr 33.3% | ₹6 Cr 40.0% | ₹10 Cr 9.1% | ₹11 Cr |
| PBT | ₹188 Cr 9.9% | ₹171 Cr 31.5% | ₹130 Cr 41.3% | ₹92 Cr 7.0% | ₹86 Cr 87.0% | ₹46 Cr 21.1% | ₹38 Cr 52.0% | ₹25 Cr |
| Tax % | 25.0% 0.0% | 25.0% 7.4% | 27.0% 3.8% | 26.0% 4.0% | 25.0% 3.8% | 26.0% 0.0% | 26.0% 30.0% | 20.0% |
| Net Profit | ₹141 Cr 10.2% | ₹128 Cr 36.2% | ₹94 Cr 38.2% | ₹68 Cr 6.3% | ₹64 Cr 88.2% | ₹34 Cr 21.4% | ₹28 Cr 40.0% | ₹20 Cr |
| EPS (₹) | 24.63 9.9% | 22.41 35.9% | 16.49 16.5% | 14.16 97.3% | 532.92 85.4% | 287.5 23.7% | 232.42 40.3% | 165.67 |
| Div Payout | 8.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹57 Cr 0.0% | ₹57 Cr 0.0% | ₹57 Cr 0.0% | ₹57 Cr 18.8% | ₹48 Cr 300.0% | ₹12 Cr 0.0% | ₹12 Cr 0.0% | ₹12 Cr 0.0% | ₹12 Cr |
| Reserves | ₹1.0K Cr 7.3% | ₹964 Cr 6.9% | ₹902 Cr 16.5% | ₹774 Cr 238.0% | ₹229 Cr 16.2% | ₹197 Cr 48.1% | ₹133 Cr 35.7% | ₹98 Cr 40.0% | ₹70 Cr |
| Borrowings | ₹344 Cr 2.4% | ₹336 Cr 0.6% | ₹338 Cr 38.0% | ₹245 Cr 3.4% | ₹237 Cr 19.1% | ₹199 Cr 332.6% | ₹46 Cr 14.8% | ₹54 Cr 25.0% | ₹72 Cr |
| Other Liabilities | ₹401 Cr 19.7% | ₹335 Cr 23.6% | ₹271 Cr 12.9% | ₹240 Cr 25.7% | ₹191 Cr 14.4% | ₹167 Cr 6.7% | ₹179 Cr 121.0% | ₹81 Cr 19.1% | ₹68 Cr |
| Total Liabilities | ₹1.8K Cr 8.5% | ₹1.7K Cr 7.9% | ₹1.6K Cr 19.1% | ₹1.3K Cr 86.9% | ₹704 Cr 22.4% | ₹575 Cr 55.4% | ₹370 Cr 51.0% | ₹245 Cr 9.9% | ₹223 Cr |
Assets | |||||||||
| Fixed Assets | ₹842 Cr 0.6% | ₹847 Cr 2.0% | ₹830 Cr 131.8% | ₹358 Cr 95.6% | ₹183 Cr 0.0% | ₹183 Cr 131.6% | ₹79 Cr 8.2% | ₹73 Cr 6.4% | ₹78 Cr |
| CWIP | ₹16 Cr 128.6% | ₹7 Cr 69.6% | ₹23 Cr 93.3% | ₹341 Cr 1450.0% | ₹22 Cr | ₹0 Cr 100.0% | ₹7 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹41 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹938 Cr 11.9% | ₹838 Cr 17.0% | ₹716 Cr 16.0% | ₹617 Cr 23.4% | ₹500 Cr 27.6% | ₹392 Cr 38.5% | ₹283 Cr 64.5% | ₹172 Cr 19.4% | ₹144 Cr |
| Total Assets | ₹1.8K Cr 8.5% | ₹1.7K Cr 7.9% | ₹1.6K Cr 19.1% | ₹1.3K Cr 86.9% | ₹704 Cr 22.4% | ₹575 Cr 55.4% | ₹370 Cr 51.0% | ₹245 Cr 9.9% | ₹223 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹117 Cr 82.8% | ₹64 Cr 56.2% | ₹146 Cr 117.9% | ₹67 Cr 13.6% | ₹59 Cr 40.5% | ₹42 Cr 35.5% | ₹31 Cr 63.2% | ₹19 Cr |
| Investing CF | ₹-107 Cr 29.6% | ₹-152 Cr 69.5% | ₹-499 Cr 448.4% | ₹-91 Cr 51.6% | ₹-188 Cr 840.0% | ₹-20 Cr 233.3% | ₹-6 Cr 33.3% | ₹-9 Cr |
| Financing CF | ₹-22 Cr 123.9% | ₹92 Cr 74.5% | ₹361 Cr 1237.0% | ₹27 Cr 78.4% | ₹125 Cr 757.9% | ₹-19 Cr 17.4% | ₹-23 Cr 155.6% | ₹-9 Cr |
| Net Cash Flow | ₹-12 Cr 400.0% | ₹4 Cr 50.0% | ₹8 Cr 166.7% | ₹3 Cr 160.0% | ₹-5 Cr 266.7% | ₹3 Cr 200.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Free Cash Flow | ₹55 Cr 150.9% | ₹-108 Cr 23.4% | ₹-141 Cr 1181.8% | ₹-11 Cr 47.6% | ₹-21 Cr 191.3% | ₹23 Cr 14.8% | ₹27 Cr 145.5% | ₹11 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 98d 1.0% | 97d 0.0% | 97d 6.7% | 104d 7.2% | 97d 21.1% | 123d 44.7% | 85d 8.6% | 93d |
| Inventory Days | 125d 5.0% | 119d 30.8% | 91d 18.2% | 77d 1.3% | 76d 29.0% | 107d 27.4% | 84d 68.0% | 50d |
| Days Payable | 141d 22.6% | 115d 1.8% | 113d 7.6% | 105d 22.1% | 86d 34.8% | 132d 43.5% | 92d 15.0% | 80d |
| Cash Conv. Cycle | 82d 18.8% | 101d 34.7% | 75d 2.6% | 77d 11.5% | 87d 12.1% | 99d 28.6% | 77d 20.3% | 64d |
| Working Capital Days | 86d 6.2% | 81d 5.2% | 77d 32.8% | 58d 56.8% | 37d 5.1% | 39d 13.3% | 45d 50.0% | 30d |
| ROCE | 15.0% 0.0% | 15.0% 21.1% | 19.0% 20.8% | 24.0% 22.6% | 31.0% 10.7% | 28.0% 7.7% | 26.0% | — |
Source: Screener.in · Lower days = better efficiency
About Innova Captab Limited
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
HealthcarePharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Innova Captab Limited share price today?
Innova Captab Limited (INNOVACAP) is currently trading at ₹1,049.7 on NSE, down 1.21% as of the last market session. Prices update daily after market close on MarketNetra.
Is Innova Captab Limited available in F&O (Futures & Options)?
Yes, Innova Captab Limited (INNOVACAP) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Innova Captab Limited 52-week high and low?
Innova Captab Limited's 52-week high is ₹1,354 and the 52-week low is ₹608. The current price of ₹1,049.7 is 22.5% below the 52W high.
What is Innova Captab Limited P/E ratio?
Innova Captab Limited's current P/E ratio is 36.7. This indicates the market is paying ₹36.7 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Innova Captab Limited options?
Innova Captab Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade INNOVACAP options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.